<2 Yaş RSV+ ASYE Yatan Hastalarda Direkt Tıbbi Maliyet Değerlendirmesi

It was found that the total direct medical hospitalization costs including the antibiotics including the RSV+LRTI median values were 334 (range: 6-21545) (mean+SD: 910±226) $, antibiotic costs median value was 24 (0-7691) (103±548) $, and non-antibiotic median value was 301 (6-18767) (789±1826) $.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Objective: This multi-center study aimed to assess the direct medical costs in patients aged between 0-2 year-old admitted to the hospital due to lower respiratory tract infection (LRTI), which was identified as respiratory syncytial virus (RSV) in 3 big pediatric hospitals for a year.

📊

Key Findings & Data:Material and Methods: During one-year period, <2-year-old LRTI patients with RSV+ and RSV were included in the study conducted in 3 different pediatric hospitals.

💡

Conclusion & Impact:It was found that the total direct medical hospitalization costs including the antibiotics including the RSV+LRTI median values were 334 (range: 6-21545) (mean+SD: 910±226) $, antibiotic costs median value was 24 (0-7691) (103±548) $, and non-antibiotic median value was 301 (6-18767) (789±1826) $.

🔬Design:Research Article

📍Scope:2016 Verileri

⚙️Variables:Domain Parameters

Abstract

Objective: This multi-center study aimed to assess the direct medical costs in patients aged between 0-2 year-old admitted to the hospital due to lower respiratory tract infection (LRTI), which was identified as respiratory syncytial virus (RSV) in 3 big pediatric hospitals for a year. Material and Methods: During one-year period, <2-year-old LRTI patients with RSV+ and RSV were included in the study conducted in 3 different pediatric hospitals. RSV was diagnosed with the detection of nasopharyngeal antigen. Direct medical costs (hospitalization, laboratory and treatment costs) were removed from the hospitals bills. Antibiotic costs of the antibiotic-treated cases were calculated independently. The indirect costs in the study were not considered and evaluated. Results: In the study, 10% of the total inpatients aged <2-years were hospitalized with LRTI. 38% (254/671) of patients with LRTI, 41% (151/368) of those with acute bronchiolitis and 34% (103/303) of those with pneumonia were RSV positive. 4% of all hospitalized cases were RSV+LRTI; nearly 88% of the RSV+LRTIs and 92% of RSVLRTIs received antibiotics (p=0.09). 10% of the RSV+LRTIs and 13% of RSVRLTIs were hospitalized in the intensive care units (p=0.19). It was found that the total direct medical hospitalization costs including the antibiotics including the RSV+LRTI median values were 334 (range: 6-21545) (mean+SD: 910±226) $, antibiotic costs median value was 24 (0-7691) (103±548) $, and non-antibiotic median value was 301 (6-18767) (789±1826) $. It was found that these values in the RSVLRTI, on the other hand, 358 (5-31938) (1028±2741) $, 33 (0-33333) (90±236)$, 320 (5-31767) (911±2625) $ respectively. 48% of RSV+LRTI cases were aged between 0-3 months and it was found that the average cost per case was in this age group was two times higher than the 4-6 months and 7-11 months age group (on average 1068, 508 and 352$ respectively). It was found that the hospitalization costs of the total of 254 RSV+ patients were $ 231,178 and the costs of the 417 RSV patients were $ 428,991. Conclusion: According to these results, RSV infections still constitute a significant part of RLTIs at <2 years of age in our country and cause an important epidemiological and economic disease burden. (J Pediatr Inf 2016; 10: 128-36)

Özet

Amaç: Çok merkezli bu çalışmada, bir yıllık sürede 3 büyük çocuk hastanesinde 0-2 yaş arası Respiratuvar Sinsityal Virüs (RSV) saptanan alt solunum yolu enfeksiyonu (ASYE) nedeniyle hastaneye yatırılan olgularda direkt tıbbi maliyet değerlendirilmesi amaçlandı. Gereç ve Yöntemler: Bir yıl süresince 3 farklı çocuk hastanesinde <2 yaş ASYE ile yatan RSV+ ve RSVolgular çalışmaya alındı. RSV tanısı nazofarengiyal antijen tespiti ile konuldu. Direkt tıbbi maliyetler (yatış, laboratuvar, tedavi maliyetleri) hastane faturalarından çıkarıldı. Antibiyotik verilen olguların antibiyotik maliyetleri ayrıca hesaplandı. Çalışmada indirekt maliyetler dikkate alınmadı ve değerlendirilmedi. Bulgular: Çalışmada toplam yatan <2 yaş olguların %10'u ASYE ile yattı. Yatan ASYE'lerin %38'i (254/671) akut bronşiyolitlerin %41 (151/368), pnömonilerin %34 (103/303) RSV pozitifti. Tüm yatan olguların %4'ü RSV+ASYE idi RSV+ASYE'lerin yaklaşık %88'i RSV-ASYE'lerin %92'si antibiyotik almıştı (p=0,09). RSV+ASYE'lerin %10'u, RSV-ASYE'lerin %13'ü yoğun bakıma yatırıldı (p=0,19). Antibiyotik dahil toplam direkt tıbbi yatış maliyetleri RSV+ASYE'de kişi başı medyan değeri 334 (ortalama+ SD: 910±226) $, olgu başına antibiyotik maliyeti medyan değeri 24 (103±548) $, olgu başına antibiyotik dışı maliyet medyan değeri 301 (789±1826) $ saptandı. RSV-ASYE'de ise bu değerler sırasıyla 358 (1028±2741) $, 33 (90±236) $, 320 (911±2625) $ bulundu. RSV+ASYE olgularının %48'i 0-3 ay arasındaydı ve bu yaş grubunda olgu başına maliyet ortalaması 4-6 ay ve 7-11 ay yaş gruplarına göre 2 kattan daha fazla bulundu (sırasıyla ortalama 1068, 508 ve 352$). Toplam 254 RSV+ olgunun yatış maliyeti 231.178$, RSV417 olgunun maliyeti ise 428,991 $ bulundu. Sonuç: Bu sonuçlara göre RSV enfeksiyonları halen <2 yaşta ASYE'lerin önemli bir kısmını oluşturmakta ve önemli bir epidemiyolojik ve ekonomik hastalık yüküne neden olmaktadır

🔖

Cite This Article

BOZDEMİR, Ş. E., ÇELEBİ, S., ÇAKIR, D., ÖZCAN, İ., SIĞIRLI, D., SALI, E., ÖZER, A., HACIMUSTAFAOĞLU, M. K. (2016). <2 Yaş RSV+ ASYE Yatan Hastalarda Direkt Tıbbi Maliyet Değerlendirmesi. Çocuk Enfeksiyon Dergisi, Cilt: 10 - Sayı: 4, 128–136. https://ajindex.com/articles/167160

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-98. [CrossRef] 2. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282: 1440-6. [CrossRef] 3. García CG, Bhore R, Soriano-Fallas A, et al. Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics 2010; 126: e1453-60. [CrossRef] 4. U.S. & World Population Clocks”. Census.gov. 2012-04-06. Retrieved 2012-04-17 (Date of access: 18.04.2013). 5. http://www.turkstat.gov.tr/PreHaberBultenleri.do?id=13425 (Date of access 18.04.2013). 6. Pouwels KB, Bozdemir SE, Yegenoglu S, et al. Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data. PLoS One 2016; 11: e0163567. [CrossRef] 7. Ajayı-Obe EK, Coen PG, Hawrami K, Aitken C, McIntosh ED, Booy R. Influenza A and respiratory syncytial virus hospital burden in young children in East London. Epidemiol Infect 2000; 136: 1046-58. 8. Hacimustafaoglu M, Celebi S, Elmas Bozdemir Ş, et al. RSV Frequency in Children below 2 Years Hospitalized for Lower Respiratory Tract Infections. Turk J Pediatr 2013; 55: 130-9. 9. Walsh EE, Hall CB. Respiratory Syncytial Virus. In: Feigin RD, Cherry JD, Harrison GJ, Kaplan SL, (eds).Feigin & Cherry’s Textbook of Pediatric Infectious Diseases. 6th edition. Philadelphia: Elsevier Saunders; 2009. p: 2462-87. 10. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with respiratory syncytial virus. International RSV Study Group. Eur J Pediatr 1998; 157: 215-20. [CrossRef] 11. Weigl JA, Puppe W, Rockahr S, Schmitt HJ. Burden of disease in hospitalized RSV-positive children in Germany. Klin Padiatr 2002; 214: 334-42. [CrossRef] 12. Wahab AA, Dawod ST, Raman HM. Clinical characteristics of respiratory syncytial virus infection in hospitalized healthy infants and young children in Qatar. J Trop Pediatr 2001; 47: 363-6. [CrossRef] 13. Samson L, Cooke C, Macdonald N. Analysis of antibiotic use and misuse in children hospitalized with RSV infection. Paediatr Child Health 1999; 4: 195-9. 14. Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003; 88: 1065-9. [CrossRef]